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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Main objective
To assess the effects of music therapy, as a primary or a supportive intervention, compared to standard care, wait-list control or no
treatment, for people with substance use disorders, to reduce substance use,the severity of substance dependence/abuse, psychological
symptoms, and substance craving; to enhance motivation for change/treatment; and for retention in treatment.
Secondary objective
To assess the impact of the number of music therapy sessions on study outcomes.
B A C K G R O U N D
Description of the condition
Substance abuse and related high-risk behaviour have a negative
impact on individuals, families, and global public health. The
World Health Organization’s (WHO) Global Status Report on Al-
cohol andHealth 2014 cites 3.3million deaths in 2012 attributable
to the harmful use of alcohol, representing 5.9% of all deaths
(WHO 2014, p.48). In addition, 5.1% of the global burden of
disease, expressed as 139 million net disability-adjusted life years,
can be attributed to alcohol consumption (WHO 2014, p.16).
Problematic use of drugs and alcohol is a widespread issue, with
approximately 27 million people worldwide engaging in problem
drug use (range 15.7 to 39 million) (UNODC 2015), and 4.1%
of the world’s population aged 15 years or older demonstrating ei-
ther harmful use of alcohol or alcohol dependence (WHO 2014).
Substance use disorders (SUDs)may be defined as the use of one or
more psychoactive substances, medically prescribed or not (WHO
1994), in a manner that results in continued use despite signifi-
cant substance-related problems in areas of cognitive, behavioural,
physiological or social functioning (DSM-V, APA 2013). People
who inject drugs are at higher risk of death due to the transmis-
sion of infectious diseases, most notably HIV, and the possibil-
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ity of fatal overdose (UNODC 2015). An estimated one in ev-
ery six problem drug users worldwide receives the necessary treat-
ment; if all problem drug users sought treatment, the resulting cost
would represent 0.3% to 0.4% of the global gross domestic prod-
uct (INCB 2013). Although the economic burden of treatment is
considerable, the costs of crime-related and healthcare provision
for untreated problem drug use remain far higher than that of
prevention and treatment (INCB 2013).
Longer lengths of stay in substance abuse treatment are associ-
ated with better engagement in aftercare programmes and lower
levels of substance use at long-term follow-up (Arbour 2011).
Better treatment retention also predicts lower recidivism rates in
criminally-convicted individuals with co-occurring substance use
and mental health disorders (Jaffe 2012). Supporting retention
in treatment remains a crucial aspect of addressing the harms
caused by SUDs, but remains one of the greatest challenges. In
the United States, approximately 26% of problem substance users
drop out of public treatment programmes (SAMHSA2014). Prob-
lem substance users who have co-occurring mental health disor-
ders demonstrate low treatment retention rates. Gender-specific
treatment retention strategies are also important for this subgroup
(Choi 2015).
Description of the intervention
Music therapy is “a systematic process of intervention wherein the
therapist helps the person to promote health, using music expe-
riences and the relationships that develop through them as dy-
namic forces of change” (Bruscia 1998, p.20). During this pro-
cess, a trained music therapist engages with the participant in a
range of active and receptive approaches to listening to, discussing,
creating, improvising and performing music. Music therapy may
incorporate varying levels of verbal processing, depending upon
client need and the theoretical orientation of the music thera-
pist. Sessions can occur with individuals, groups, or with commu-
nities, and may include various approaches such as songwriting,
discussion of song lyrics, instrumental or vocal improvisation, or
both, music performance, and music-assisted relaxation. Music
therapymay be practised from a variety of theoretical orientations,
and in the setting of substance abuse treatment may include ele-
ments of cognitive-behavioural, humanistic, psychodynamic and/
or neurobiological theory, among others. Music therapists work
with abstinence-based, controlled use, and in harm reduction con-
texts (Aldridge 2010;Ghetti 2004), in inpatient treatment centres,
community mental health centres, adult day healthcare centres,
state and general hospitals, therapeutic communities, and aftercare
programmes (Aldridge 2010; Ghetti 2004; Silverman 2009).
The modern profession of music therapy began in the 1940s and
1950s, with the establishment of academic and clinical training
programmes in the United States, Austria, and the United King-
dom, followed by developments in other parts of Europe, North
and South America, Africa, Australia and Asia (Bunt 2014). The
academic preparation required for professional practice currently
varies by country, although many countries require master’s level
training in music therapy.
The music therapy process is potentially well-positioned to meet
the needs of people in substance abuse treatment. Within each
music therapy session, interactions between therapist and partic-
ipant are designed to “motivate and sustain the client’s engage-
ment in the therapeutic music process” and to move them closer
to therapeutic goals (Bruscia 2014, p.37). Furthermore, sessions
and music therapy approaches are sequenced over time in direct
relation to the participant’s needs and readiness, building upon
their resources and introducing therapeutic challenges when ap-
propriate (Bruscia 2014).
How the intervention might work
Motivation for treatment may be understood in terms of the dis-
tinct dimensions of readiness and resistance, where readiness rep-
resents the level of interest in and commitment to substance abuse
treatment, and resistance represents scepticism toward the poten-
tial benefits of treatment or opposition to engaging in treatment
(Longshore 2006). The degree of readiness serves as a significant
predictor of treatment retention, while the level of resistance pre-
dicts actual drug use (Longshore 2006). Promoting treatment re-
tention as a means of enabling better overall outcomes therefore
requires improving readiness for treatment and reducing resistance
to treatment.
Music therapy provides a broad range of effects for people with
SUDs, from neurobiological to social and cultural levels (Aldridge
2010). Music therapists are informed by an awareness of the neu-
robiological impacts of music on human emotions and behaviour,
and consider this level of influence as they engage with partici-
pants in music-making. The social and interpersonal benefits of
engaging in music help provide communal experiences that offer
opportunities for connection and expression.
At a neurobiological level, music that provokes peak experiences
stimulates neural reward and emotion systems similar to those that
are activated by drugs of abuse (Blood 2001). Due to these similar
patterns of neural activity, music has the potential to promote
positive mood states, including euphoria, and to enable emotional
regulation (Koelsch 2015; SenaMoore 2013). As music provides a
means of promoting positive mood states (Koelsch 2014), it may
consequently buffer against the risk of relapse that is associated
with negative mood states (Koob 2013). Furthermore, pleasurable
music can promote the release of dopamine to positively affect
the reward system (Blum 2010), and can inhibit activity in areas
of the limbic system in a way that inhibits transmission of pain
perception (Neugebauer 2004).
Since music readily acts upon neural activity, special consideration
is necessary when using music therapeutically with people with
SUDs. Individuals with SUDs can experience a decrease in sub-
stance craving after listening to songs they identify as helping them
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stay clean/sober, but they may also experience an increase in sub-
stance craving after listening to songs they identify asmaking them
want to use substances (Short 2015). Thus, gaining awareness of
healthy and unhealthy uses of music, and of the context of how
music is perceived are important aspects of music therapy within
substance abuse treatment (McFerran 2016). Furthermore, strong
personal associations between music and substance use, some of
which can contribute to relapse when left unexamined, can be suc-
cessfully addressed and reversed in music therapy (Horesh 2010).
Individuals learn to recognise, retrain and integrate state-specific
emotional responses to music as part of their lifestyle.
People with SUDs who participate in music therapy may experi-
ence increasedmotivation to engage in treatment, which may then
generalise to other facets of substance abuse treatment (Horesh
2010). Active engagement in music therapy can alleviate anxiety
and depression in people with serious mental disorders (Mössler
2011), and a reduction in such symptoms may then improve ad-
herence to treatment and promote improved general functioning.
By motivating engagement in treatment, facilitating development
of therapeutic rapport, and musically approaching strong emo-
tions as a means of expanding coping skills (Ghetti 2013), music
therapy may promote readiness for treatment and reduce resis-
tance, thereby promoting treatment retention and the subsequent
reduction of substance use.
Why it is important to do this review
Music therapy is used as a non-pharmacological psychotherapeutic
intervention within acute-phase treatment for detoxification, and
in community aftercare programmes for people with substance use
disorders (Aldridge 2010; Silverman 2009), with individual stud-
ies demonstrating improvements in motivation to engage in treat-
ment and reduction in psychological symptoms (Albornoz 2011;
Silverman 2012). Previous reviews (Mays 2008; Silverman 2003)
of music therapy for substance use disorders are either out of date
or did not include meta-analysis of study outcomes. Due to the
increasing volume of international research into music therapy for
substance use disorders, and the need to establish an evidence base
for practice and policy, a rigorous and comprehensive systematic
review of randomised controlled trials specific to this topic is war-
ranted.
O B J E C T I V E S
Main objective
To assess the effects of music therapy, as a primary or a supportive
intervention, compared to standard care, wait-list control or no
treatment, for people with substance use disorders, to reduce sub-
stance use,the severity of substance dependence/abuse, psycholog-
ical symptoms, and substance craving; to enhance motivation for
change/treatment; and for retention in treatment.
Secondary objective
To assess the impact of the number of music therapy sessions on
study outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant parallel-group randomised controlled trials (RCTs),
including the first phase of cross-over trials.
Types of participants
People with problem substance use, with a formal diagnosis of
substance use disorder (SUD). Substances to be considered are
illicit drugs, medication, and alcohol. We exclude nicotine addic-
tion, due to the dissimilar impact on social and functional do-
mains. We exclude non-substance addiction (e.g. Internet addic-
tion, gambling addiction). Diagnosis of substance use disorder
will be based upon diagnostic criteria from DSM-IV-TR (APA
2000) or DSM-V (APA 2013), and from the International Clas-
sification of Diseases 10 Version: Online 2016 (ICD-10) (WHO
2016), codes F10 to F16 (mental and behavioural disorders due
to use of alcohol, opioids, cannabinoids, sedatives or hypnotics,
cocaine, stimulants, or hallucinogens), and F18 to F19 (mental
and behavioural disorders due to use of volatile solvents or multi-
ple drug use and use of other psychoactive substances), with the
exclusion of caffeine (part of F15). There will be no restrictions by
age or other participant characteristics. Participants may be dual-
diagnosed with mental health problems. Participants may receive
intervention in inpatient, outpatient, therapeutic community, or
supportive aftercare settings.
Types of interventions
Experimental intervention:
Music therapy or music therapy added to standard care.
The intervention should be labeled ’music therapy’ (MT), and
should be conducted by a trained music therapist. MT involves
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a music therapist and one or more participants, mindfully engag-
ing in music experiences as a means of helping them to achieve
their highest potentials of health (Bruscia 2014). MT interven-
tions may consist of a variety of receptive or active approaches that
use music to promote therapeutic change. Receptive approaches
may include listening to music as a basis for guided discussion and
examination of feelings and thoughts or to impact on mood, as
well as other aims. Active approaches may include opportunities
for the participant to interact with music and music-making pro-
cesses through songwriting, singing, or playing instruments. We
will include both individual and group music therapy interven-
tions. MT may be integrated with a specific treatment approach
(e.g. cognitive behaviour therapy), and can be any length of ses-
sion and course of treatment. MT may be offered either with or
without standard care (as defined below).
Control intervention:
Standard care alone:
Standard care represents treatment as usual, and includes any con-
ventional treatment (including pharmacotherapy) offered at the
treatment setting as long as that treatment does not involve MT.
Examples of services offered as part of standard care for substance
use disorders include: counselling, case management, pharma-
cotherapy including methadone maintenance treatment, pharma-
cological detoxification, etc.
Wait-list control:
Wait list consists of participants assigned to a waiting list to receive
MT after the active treatment group. Wait-list control may be
presented with or without standard care.
Types of comparisons:
• MT plus standard care versus standard care alone
(including wait list for MT)
• MT with no additional treatment versus no treatment
(including wait list for MT)
Types of outcome measures
Outcomes can be measured and reported either dichotomously
or continuously. Data sources may include both standardised and
non-standardised instruments. We will include data from rating
scales when they are from participant self-report or rated by an
independent rater (i.e. not the music therapist).
Primary outcomes
1. Reduction in substance use in terms of amount, frequency,
or peak use (as measured by self-report, report by independent
evaluators, urine analysis or blood samples).
2. Retention in treatment (based on reported study dropout
rates).
3. Severity of substance dependence/abuse, as measured by
validated scales (e.g. Addiction Severity Index (ASI), Drinking
Inventory Consequences (DrInC), or the Severity of
Dependence Scale (SDS)).
We will collect outcomes reported immediately following comple-
tion of the intervention, short-term follow-up up to three months
after completion of the intervention, and long-term follow-up at
more than three months after completion of the intervention.
Secondary outcomes
1. Cessation of substance use (as measured by self-report,
report by independent evaluators, urine analysis, or blood
samples).
2. Reduction of psychological symptoms (e.g. depression,
anxiety, anger), e.g. measured by Beck Depression Inventory
(BDI), Brief Symptom Inventory (BSI), state portion of the
State-Trait Anxiety Inventory (STAI), or visual analogue scales.
3. Improvement in motivation for treatment/change, e.g.
measured by Readiness to Change Questionnaire (RCQ), Stages
of Change Readiness and Treatment Eagerness Scale
(SOCRATES), University of Rhode Island Change Assessment
Scale (URICA), or visual analogue scales.
4. Substance craving, e.g. measured by Brief Substance
Craving Scale (BSCS), or visual analogue scales.
5. Serious adverse events (e.g. relapse requiring hospitalisation,
suicide attempts, or suicide).
Some people with SUDs have personal goals of reducing harm
from substance use, but do not have a goal of maintaining absti-
nence. For this reason, we propose cessation of substance use as a
secondary outcome. We will measure serious adverse events as a
binary variable related to the presence or absence of adverse events,
including relapse requiring hospitalisation, suicide attempts, or
suicide.
Search methods for identification of studies
Electronic searches
The electronic searches will include the following databases:
• the Cochrane Drugs and Alcohol Group’s Specialised
Register of Trials;
• the Cochrane Central Register of Controlled Trials
(CENTRAL, most recent issue);
• MEDLINE (PubMed) (January 1966 to present);
• Embase (embase.com) (January 1974 to present);
• CINAHL (EBSCOhost) (1982 to present);
• ERIC (eric.ed.gov) (1964 to present);
• ISI Web of Science;
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• PsycINFO (EBSCOhost) (1872 to present);
• International Bibliography of the Social Sciences (IBSS)
(1951 to present);
• ProQuest Dissertations & Theses (1997 to present);
• Google Scholar.
We will not impose any restrictions by language, date, gender, age
or tag terms. We will search databases by selecting medical subject
heading (MeSH) terms and free-text terms relating to substance
use and to music therapy. The PubMed search strategy is given
in Appendix 1. We will model search strategies for the remaining
databases after the strategy for PubMed, with variations as required
by each additional database. The Information Specialist of the
Cochrane Drugs and Alcohol Group (CDAG) will develop and
apply search strategies for electronic searches.
In addition, we will search for ongoing clinical trials and unpub-
lished studies via internet searches of the following sites:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).
Searching other resources
Handsearching and reference searching:
We will handsearch the reference lists of all included studies. We
will also examine the reference lists of relevant review articles (e.g.
Mays 2008; Silverman 2003).
Data collection and analysis
Selection of studies
We will use the Covidence software platform for citation screen-
ing, includingmerging search results and removing duplicates, and
for full-text review. Two review authors and content area experts
(two of the following: XJC, JF, CGh) will independently exam-
ine each title and abstract to remove obviously irrelevant reports,
and a third review author and methodologist (CGo) will resolve
disagreements. We will then obtain full texts for all potentially
relevant reports, and link together multiple reports of the same
study when applicable. Two review authors (XJC, CGh) will in-
dependently examine each full-text report to determine eligibility,
resolving disagreements in consultation with the third and fourth
review authors (JF, CGo). We will contact investigators when nec-
essary, to clarify study eligibility.
Data extraction and management
Two review authors (CGh, XJC) will independently perform data
extraction using Covidence, and will export data to Review Man-
ager 5. When necessary, we will contact investigators to obtain
missing data. We will resolve disagreements in consultation with
the remaining two review authors (JF, CGo), and will archive their
content and resolution. We will extract information from each
study regarding:
• methods (including design and aspects related to assessing
risk of bias);
• country and setting;
• characteristics and number of participants;
• characteristics of experimental and comparison groups,
including the number of participants allocated to each;
• outcomes and time points;
• results;
• key conclusions/remarks of study authors.
Assessment of risk of bias in included studies
Two review authors (XJC, CGh) will independently assess risks
of bias using the Cochrane ’Risk of bias’ tool (Higgins 2011) in
conjunctionwith theCovidence software platform.Wewill resolve
disagreements through consultation with a third review author
andmethodologist (CGo). The first part of the tool describes what
was reported to have happened in the study, while the second part
assigns a judgement relating to the risk of bias for that entry, as
low, high or unclear risk. We will make such judgements using
the criteria indicated by the Cochrane Handbook for Systematic
Reviews of Interventions, adapted to the addiction field. Appendix
2 includes a detailed description of the ’Risk of bias’ criteria to be
used. The seven domains to be assessed include:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and providers (performance bias);
• blinding of outcome assessors (detection bias);
• incomplete outcome data (attrition bias);
• selective outcome reporting (reporting bias);
• other potential sources of bias.
Wewill consider blinding of participants and providers, and blind-
ing of outcome assessors (avoidance of performance bias and de-
tection bias) separately for objective outcomes (e.g. reduction or
cessationof substance usemeasured by urine analysis or blood sam-
ples, retention in treatment, serious adverse events) and subjective
outcomes (e.g. participant self-report of substance use/cessation,
severity of substance dependence, psychological symptoms, mo-
tivation for treatment/change, substance craving). We will assess
incomplete outcome data for each outcome (avoidance of attri-
tion bias), with the exception of ’retention in treatment.’ Other
potential threats to validity could include contamination of con-
ditions, differences between groups at baseline, or bias introduced
by elements of study design.We plan to include all eligible studies,
regardless of the level of the risks of bias, when presenting main
findings for each outcome; however, we will discuss the risks of
bias and provide a cautious interpretation within the Discussion
and Conclusions sections. For attrition bias, we will consider the
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impact of high attrition rates, i.e. studies with attrition rates greater
than 20%.
Measures of treatment effect
Dichotomous data
We will calculate the risk ratio (RR) and corresponding 95% con-
fidence interval (95% CI) for dichotomous data.
Continuous data
For continuous data from parallel-group RCTs, we will select the
mean and standard deviation (SD) end point data for experimen-
tal and control groups at three different time points: immediately
post-intervention, short-term follow-up (up to three months after
completion of the intervention), and long-term follow-up (more
than three months after completion of the intervention). When
outcomes are measured on the same scale or can be transferred to
the same scale in all studies, we will calculate the mean difference
(MD) on the original metric. When studies use different scales
to measure the same outcome, we will calculate the standardised
mean difference (SMD) and corresponding 95% CI for contin-
uous outcomes. We will standardise SMDs by pooling standard
deviations between participants, rather than standard deviations
of the differences within participants.
Unit of analysis issues
Cross-over trials
When appropriate, wewill combine results of cross-over trials with
those of parallel-group trials. Due to the likelihood of carry-over
effects in cross-over trials of music therapy, we will only analyse
data from the first phase (i.e. before cross-over) of any included
cross-over trial.
Cluster-randomised trials
When studies account for clustering in their analysis, inclusion
of the data in meta-analysis is straightforward. If clustering is not
accounted for in an included study, we will attempt to contact the
study investigators to obtain the intra-class correlation coefficient
(ICC) of their clustered data, and will use accepted methods for
handling such data. If we are unable to obtain the ICC, we will
use external estimates from similar studies (Higgins 2011).
Studies with multiple treatment groups
When studies have more than one relevant music therapy inter-
vention, we will combine all such experimental groups into a sin-
gle group, as recommended by the Cochrane Handbook (Higgins
2011). Similarly, when studies have more than one relevant con-
trol group, we will combine these into a single control group.
Dealing with missing data
We will make up to three attempts to contact investigators by
email to request missing data. We intend to follow intention-to-
treat principles and to include all known data from all randomised
participants. We will use the following sensitivity analyses to ex-
amine the impact of missing data. For continuous outcomes, we
will remove studies with high attrition (more than 20%). For di-
chotomous outcomes, we will assume that the unobserved cases
have a negative outcome. We will report on the potential impact
of missing data when assessing risks of bias.
Assessment of heterogeneity
If the number of included studies is low or studies have small sam-
ple size, or both, statistical tests for heterogeneity may have low
power and be difficult to interpret (Higgins 2011). We plan to
conduct descriptive analyses of heterogeneity, by visually examin-
ing forest plots for consistency of results and by calculating the I2
statistic, which represents the percentage of effect estimate variabil-
ity that is due to heterogeneity instead of sampling error (Higgins
2011). We plan to supplement the I2 statistic with a calculation
of the Chi2 statistic to assess the likelihood that the heterogeneity
was genuine, and to consider possible sources of heterogeneity.
Assessment of reporting biases
We plan to test for asymmetry of funnel plots when at least 10
studies are included in ameta-analysis, and to explore likely reasons
for asymmetry when it is present.
Data synthesis
We will combine the outcomes from the individual trials through
meta-analysis where possible (comparability of intervention and
outcomes between trials), using a random-effects model, because
we expect a certain degree of heterogeneity among trials. In cases
where meta-analysis is not appropriate, we will report results for
each individual study.
Subgroup analysis and investigation of heterogeneity
Whenwe detect heterogeneity, we plan to use subgroup analyses to
examine the impact of the number of sessions, type of substance,
and presence of dual-diagnosis (i.e. substance use disorder and
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mental disorder). For subgroup analysis of the number of sessions,
we will use the following cut-off points for respective subgroups:
three sessions or more versus one or two sessions for outcomes
that might show an effect of short intervention, such as are found
in detoxification settings (i.e. retention in treatment, reduction
in psychological symptoms, improvement in motivation for treat-
ment/change, substance craving); and 10 or more sessions versus
fewer than 10 sessions for outcomes typically requiring longer-
term treatment, such as those within rehabilitation settings (i.e. re-
duction in substance use, severity of substance dependence/abuse,
cessation of substance use, serious adverse events).
Sensitivity analysis
We plan to perform a series of sensitivity analyses of the review
outcomes, removing trials with high attrition rates (i.e. studies
with attrition rates higher than 20%), and trials with a high risk
of detection bias.
Grading of evidence
We will assess the overall quality of evidence for the primary out-
comeusing theGRADE system.TheGRADEWorkingGrouphas
developed a system for grading the quality of evidence (GRADE
2004;Guyatt 2008;Guyatt 2011), which takes into account issues
related both to internal and external validity, such as directness,
consistency, imprecision of results and publication bias.
TheGRADE systemuses the following criteria for assigning grades
of evidence:
• High: We are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: We are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low: Our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
• Very low: We have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of effect.
Grading is decreased for the following reasons:
• Serious (-1) or very serious (-2) study limitation for risk of
bias.
• Serious (-1) or very serious (-2) inconsistency between
study results.
• Some (-1) or major (-2) uncertainty about directness (the
correspondence between the population, the intervention, or the
outcomes measured in the studies actually found and those
under consideration in our systematic review).
• Serious (-1) or very serious (-2) imprecision of the pooled
estimate (-1).
• Publication bias strongly suspected (-1).
’Summary of findings’ table
We will include a ‘Summary of findings’ table to present the main
findings of the review in a transparent and simple tabular format.
The ’Summary of findings’ table will include:
• a list of all important outcomes, both desirable and
undesirable;
• a measure of the typical burden of these outcomes (e.g.
illustrative comparative risk);
• absolute and relative magnitude of effect;
• number or participants and studies addressing these
outcomes;
• a rating of the overall quality of evidence for each outcome;
• space for comments.
The ‘Summary of findings’ table will include all primary outcomes
(substance use, retention in treatment, severity of substance de-
pendence/abuse) and four secondary outcomes of the review (re-
duction of psychological symptoms, improvement in motivation
for treatment/change, substance craving, serious adverse events).
We will use GRADEprofiler (GRADEpro) to assist in the prepa-
ration of the ‘Summary of findings’ table.
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A P P E N D I C E S
Appendix 1. PubMed search strategy
1. Substance-Related Disorders[MeSH]
2. Amphetamines[MeSH] OR Cannabis[MeSH] OR Cocaine[MeSH] OR Designer Drugs[MeSH] OR Heroin[MeSH] OR
Methamphetamine[MeSH] OR Narcotics[MeSH] OR Street Drugs[MeSH] OR amphetamine*[tiab] OR drug*[tiab] OR
polydrug[tiab] OR substance[tiab] OR cannabis[tiab] OR cocaine[tiab] OR “hash oil*”[tiab] OR hashish[tiab] OR heroin[tiab] OR
lsd[tiab] OR marihuana[tiab] OR marijuana[tiab] OR methadone[tiab] OR mdma[tiab] OR morphine[tiab] OR ecstasy[tiab] OR
methamphetamine*[tiab] OR narcotics[tiab] OR opioid*[tiab] OR opiate*[tiab] OR opium[tiab]
3. #1 OR #2
4. abstin*[tiab] OR abstain*[tiab] OR abuse*[tiab] OR addict*[tiab] OR dependen*[tiab] OR misuse[tiab] OR overdose[tiab] OR
withdrawal*[tiab] OR disorder*[tiab]
5. #3 AND #4
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6. Alcohol Drinking[MeSH]
7. ((alcohol*[tiab] AND (abstain*[tiab] OR abstin*[tiab] OR abus*[tiab] OR addict*[tiab] OR consum*[tiab] OR dependen*[tiab]
OR disorder*[tiab] OR drink*[tiab] OR excess*[tiab] OR misus*[tiab] OR problem*[tiab] OR risk*[tiab] OR withdrawal*[tiab]))
8. #5 OR #6 OR #7
9. “Music Therapy”[Mesh]
10. “Music”[Mesh]
11. music*[tiab]
12. sing[tiab] OR singing[tiab] OR song*[tiab] OR choral*[tiab] OR choir*[tiab] OR melod*[tiab] OR lyric*[tiab]
13. #9 OR #10 OR #11 OR #12
14. randomized controlled trial[pt]
15. controlled clinical trial[pt]
16. randomized[tiab]
17. placebo[tiab]
18. drug therapy[sh]
19. randomly[tiab]
20. trial[tiab]
21. groups[tiab]
22. groups[tiab]
23. #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
24. (animals[mh] NOT humans[mh])
25. #23 NOT #24
26. #8 AND #13 AND #25
Appendix 2. Criteria for the assessment of risk of bias
Item Judgement Description
1 Random sequence generation (selec-
tion bias)
Low risk The investigators describe a random component in the sequence gen-
eration process such as: random-number table; computer random-
number generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimisation
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement
of the clinician; preference of the participant; results of a laboratory
test or a series of tests; availability of the intervention
Unclear risk Insufficient information about the sequence generation process to per-
mit judgement of ‘Low risk’ or ‘High risk’
2 Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment be-
cause one of the following, or an equivalent method, was used
to conceal allocation: central allocation (including telephone, web-
based, and pharmacy-controlled randomisation); sequentially-num-
bered drug containers of identical appearance; sequentially-numbered,
opaque, sealed envelopes
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(Continued)
High risk Investigators enrolling participants could possibly foresee assignments
and thus introduce selection bias because one of the following meth-
ods was used: open random allocation schedule (e.g. a list of random
numbers); assignment envelopes without appropriate safeguards (e.g.
if envelopes were unsealed or non-opaque or not sequentially num-
bered); alternation or rotation; date of birth; case record number; any
other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High
risk’. This is usually the case if the method of concealment is not de-
scribed or not described in sufficient detail to allow a definite judge-
ment
3 Blinding of participants and providers
(performance bias)
Objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding; Blinding
of participants and key study personnel ensured, and unlikely that the
blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding; Blinding of key study participants and
personnel attempted, but likely that the blinding could have been
broken, and the outcome is likely to be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High
risk’; the study did not address this outcome
4 Blinding of participants and providers
(performance bias)
Subjective outcomes
Low risk Blinding of participants and providers ensured, and unlikely that the
blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding; blinding of key study participants and
personnel attempted, but likely that the blinding could have been
broken, and the outcome is likely to be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High
risk’; the study did not address this outcome
5 Blinding of outcome assessor (detec-
tion bias)
Objective outcomes
Low risk No blinding of outcome assessment, but the review authors judge that
the outcome measurement is not likely to be influenced by lack of
blinding; Blinding of outcome assessment ensured, and unlikely that
the blinding could have been broken
High risk No blinding of outcome assessment, and the outcome measurement
is likely to be influenced by lack of blinding; blinding of outcome
assessment, but likely that the blinding could have been broken, and
the outcomemeasurement is likely to be influenced by lack of blinding
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(Continued)
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High
risk’; the study did not address this outcome
6 Blinding of outcome assessor (detec-
tion bias)
Subjective outcomes
Low risk Blinding of outcome assessment ensured, and unlikely that the blind-
ing could have been broken
High risk No blinding of outcome assessment, and the outcome measurement
is likely to be influenced by lack of blinding; blinding of outcome
assessment, but likely that the blinding could have been broken, and
the outcomemeasurement is likely to be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High
risk’; the study did not address this outcome
7 Incomplete outcome data (attrition
bias)
For all outcomes except retention in
treatment
Low risk No missing outcome data;
Reasons for missing outcome data unlikely to be related to true out-
come (for survival data, censoring unlikely to be introducing bias);
Missing outcomedata balanced innumbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a clinically
relevant impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference inmeans
or standardised difference in means) among missing outcomes not
enough to have a clinically relevant impact on observed effect size;
Missing data have been imputed using appropriate methods;
All randomised participants are reported/analysed in the group they
were allocated to by randomisation, irrespective of noncompliance and
co-interventions (intention-to-treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
interventions groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically rele-
vant bias in intervention effect estimate; for continuous outcome data,
plausible effect size (difference in means or standardised difference in
means) among missing outcomes enough to induce clinically relevant
bias in observed effect size;
‘As-treated’ analysis donewith substantial departure of the intervention
received from that assigned at randomisation
Unclear risk Insufficient reporting of attrition/exclusions to permit judgement of
‘Low risk’ or ‘High risk’ (e.g. number randomisednot stated, no reasons
for missing data provided; the study did not address this outcome)
8 Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s prespecified (pri-
mary and secondary) outcomes that are of interest in the review have
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(Continued)
been reported in the prespecified way;
The study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were pre-
specified (convincing text of this nature may be uncommon)
High risk Not all of the study’s prespecified primary outcomes have been re-
ported; One or more primary outcomes is reported using measure-
ments, analysis methods or subsets of the data (e.g. subscales) that were
not prespecified; one or more reported primary outcomes were not
prespecified (unless clear justification for their reporting is provided,
such as an unexpected adverse effect); one or more outcomes of in-
terest in the review are reported incompletely so that they cannot be
entered in a meta-analysis; the study report fails to include results for
a key outcome that would be expected to have been reported for such
a study
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High
risk’
9 Other sources of bias Low risk The study appears to be free of other sources of bias
High risk There is at least one important risk of bias. For example, the study: had
a potential source of bias related to the specific study design used; or
has been claimed to have been fraudulent; or had some other problem
Unclear risk There may be a risk of bias, but there is either: insufficient informa-
tion to assess whether an important risk of bias exists; or insufficient
rationale or evidence that an identified problem will introduce bias
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